Paquinimod is primarily investigated for its immunomodulatory properties, making it a potential therapeutic agent in autoimmune diseases and fibrosis. It has shown promise in conditions like systemic sclerosis, where it helps reduce inflammation and fibrosis by modulating the immune response. Additionally, it is being studied for its role in cancer immunotherapy, as it may enhance the body's ability to fight tumors by altering the tumor microenvironment. Its ability to target specific immune pathways also makes it a candidate for treating chronic inflammatory diseases, such as multiple sclerosis, by potentially slowing disease progression and alleviating symptoms.